Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Structural recognition mechanisms between human Src homology domain 3 (SH3) and ALG-2-interacting protein X (Alix).

Shi X, Betzi S, Lugari A, Opi S, Restouin A, Parrot I, Martinez J, Zimmermann P, Lecine P, Huang M, Arold ST, Collette Y, Morelli X.

FEBS Lett. 2012 Jun 21;586(13):1759-64. doi: 10.1016/j.febslet.2012.05.017. Epub 2012 May 26.

2.

A specific protein disorder catalyzer of HIV-1 Nef.

Lugari A, Breuer S, Coursindel T, Opi S, Restouin A, Shi X, Nazabal A, Torbett BE, Martinez J, Collette Y, Parrot I, Arold ST, Morelli X.

Bioorg Med Chem. 2011 Dec 15;19(24):7401-6. doi: 10.1016/j.bmc.2011.10.051. Epub 2011 Oct 20.

PMID:
22061824
3.

Stably expressed APOBEC3F has negligible antiviral activity.

Miyagi E, Brown CR, Opi S, Khan M, Goila-Gaur R, Kao S, Walker RC Jr, Hirsch V, Strebel K.

J Virol. 2010 Nov;84(21):11067-75. doi: 10.1128/JVI.01249-10. Epub 2010 Aug 11.

4.

Identification and biophysical assessment of the molecular recognition mechanisms between the human haemopoietic cell kinase Src homology domain 3 and ALG-2-interacting protein X.

Shi X, Opi S, Lugari A, Restouin A, Coursindel T, Parrot I, Perez J, Madore E, Zimmermann P, Corbeil J, Huang M, Arold ST, Collette Y, Morelli X.

Biochem J. 2010 Oct 1;431(1):93-102. doi: 10.1042/BJ20100314.

PMID:
20670214
5.

Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn.

Brignatz C, Paronetto MP, Opi S, Cappellari M, Audebert S, Feuillet V, Bismuth G, Roche S, Arold ST, Sette C, Collette Y.

Mol Cell Biol. 2009 Dec;29(24):6438-48. doi: 10.1128/MCB.00398-09. Epub 2009 Oct 5.

6.

Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein.

Betzi S, Restouin A, Opi S, Arold ST, Parrot I, Guerlesquin F, Morelli X, Collette Y.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19256-61. Epub 2007 Nov 27.

7.

HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.

Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, Takeuchi H, Strebel K.

Virology. 2008 Mar 1;372(1):136-46. Epub 2007 Nov 19.

8.

Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.

Campbell GR, Senkaali D, Watkins J, Esquieu D, Opi S, Yirrell DL, Kaleebu P, Loret EP.

Vaccine. 2007 Dec 5;25(50):8441-7. Epub 2007 Oct 22.

PMID:
17997200
9.

Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K.

J Virol. 2007 Dec;81(24):13346-53. Epub 2007 Oct 10.

10.

Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.

Kao S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Takeuchi H, Strebel K.

Virology. 2007 Dec 20;369(2):329-39. Epub 2007 Sep 6.

11.

Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.

Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, Kao S, Strebel K.

Retrovirology. 2007 Jul 16;4:48.

12.

Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.

Takeuchi H, Buckler-White A, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Kao S, Sokolskaja E, Pertel T, Luban J, Strebel K.

J Virol. 2007 Aug;81(15):8080-90. Epub 2007 May 23.

13.

Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.

Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K.

J Virol. 2007 Aug;81(15):8236-46. Epub 2007 May 23.

14.

Monomeric APOBEC3G is catalytically active and has antiviral activity.

Opi S, Takeuchi H, Kao S, Khan MA, Miyagi E, Goila-Gaur R, Iwatani Y, Levin JG, Strebel K.

J Virol. 2006 May;80(10):4673-82.

15.

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.

Watkins JD, Lancelot S, Campbell GR, Esquieu D, de Mareuil J, Opi S, Annappa S, Salles JP, Loret EP.

Retrovirology. 2006 Jan 27;3:8.

16.

Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.

Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K.

J Virol. 2005 May;79(9):5870-4.

17.

HIV-1 Tat protein enhances microtubule polymerization.

de Mareuil J, Carre M, Barbier P, Campbell GR, Lancelot S, Opi S, Esquieu D, Watkins JD, Prevot C, Braguer D, Peyrot V, Loret EP.

Retrovirology. 2005 Feb 3;2:5.

18.

Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.

Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K.

Retrovirology. 2004 Sep 17;1:27.

19.

Full-length HIV-1 Tat protein necessary for a vaccine.

Opi S, Péloponèse JM Jr, Esquieu D, Watkins J, Campbell G, De Mareuil J, Jeang KT, Yirrell DL, Kaleebu P, Loret EP.

Vaccine. 2004 Aug 13;22(23-24):3105-11.

PMID:
15297062
20.

A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.

Montembault M, Vo-Thanh G, Deyine A, Fargeas V, Villiéras M, Adjou A, Dubreuil D, Esquieu D, Grégoire C, Opi S, Péloponèse JM, Campbell G, Watkins J, de Mareuil J, Aubertin AM, Bailly C, Loret E, Lebreton J.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1543-6.

PMID:
15006399
21.

Ca2+/calmodulin transfers the membrane-proximal lipid-binding domain of the v-SNARE synaptobrevin from cis to trans bilayers.

de Haro L, Ferracci G, Opi S, Iborra C, Quetglas S, Miquelis R, Lévêque C, Seagar M.

Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1578-83. Epub 2004 Feb 2.

22.

Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.

Opi S, Péloponèse JM Jr, Esquieu D, Campbell G, de Mareuil J, Walburger A, Solomiac M, Grégoire C, Bouveret E, Yirrell DL, Loret EP.

J Biol Chem. 2002 Sep 27;277(39):35915-9. Epub 2002 Jun 21.

23.

Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.

Grégoire C, Péloponèse JM Jr, Esquieu D, Opi S, Campbell G, Solomiac M, Lebrun E, Lebreton J, Loret EP.

Biopolymers. 2001;62(6):324-35.

PMID:
11857271
24.

Evolution of maurotoxin conformation and blocking efficacy towards Shaker B channels during the course of folding and oxidation in vitro.

di Luccio E, Matavel A, Opi S, Regaya I, Sandoz G, M'barek S, Carlier E, Estève E, Carrega L, Fajloun Z, Rochat H, Loret E, de Waard M, Sabatier JM.

Biochem J. 2002 Jan 15;361(Pt 2):409-16.

25.

1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein.

Péloponèse JM Jr, Grégoire C, Opi S, Esquieu D, Sturgis J, Lebrun E, Meurs E, Collette Y, Olive D, Aubertin AM, Witvrow M, Pannecouque C, De Clercq E, Bailly C, Lebreton J, Loret EP.

C R Acad Sci III. 2000 Oct;323(10):883-94.

PMID:
11098404

Supplemental Content

Support Center